The first is obviously what you just mentioned, which is the direct correlation between the reduction and the reduction of parenteral nutrition, the reduction in cost.

FORBES: Are Drugs for Ultra-Rare Diseases the Future of Biotech? Francois Nader of NPS Weighs In